187 related articles for article (PubMed ID: 27129239)
21. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.
Victor BC; Anbalagan A; Mohamed MM; Sloane BF; Cavallo-Medved D
Breast Cancer Res; 2011; 13(6):R115. PubMed ID: 22093547
[TBL] [Abstract][Full Text] [Related]
22. RhoC and ROCKs regulate cancer cell interactions with endothelial cells.
Reymond N; Im JH; Garg R; Cox S; Soyer M; Riou P; Colomba A; Muschel RJ; Ridley AJ
Mol Oncol; 2015 Jun; 9(6):1043-55. PubMed ID: 25677806
[TBL] [Abstract][Full Text] [Related]
23. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
Kaushal N; Durmaz YY; Bao L; Merajver SD; ElSayed ME
Mol Pharm; 2015 Jul; 12(7):2406-17. PubMed ID: 26020100
[TBL] [Abstract][Full Text] [Related]
24. p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.
Rosenthal DT; Iyer H; Escudero S; Bao L; Wu Z; Ventura AC; Kleer CG; Arruda EM; Garikipati K; Merajver SD
Cancer Res; 2011 Oct; 71(20):6338-49. PubMed ID: 21862636
[TBL] [Abstract][Full Text] [Related]
25. Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC.
Wu D; Asiedu M; Wei Q
Oncogene; 2009 Jun; 28(22):2219-30. PubMed ID: 19421144
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of caveolin-1 in inflammatory breast cancer cells enables IBC-specific gene delivery and prodrug conversion using histone-targeted polyplexes.
Ross NL; Sullivan MO
Biotechnol Bioeng; 2016 Dec; 113(12):2686-2697. PubMed ID: 27241022
[TBL] [Abstract][Full Text] [Related]
27. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.
Lo AC; Kleer CG; Banerjee M; Omar S; Khaled H; Eissa S; Hablas A; Douglas JA; Alford SH; Merajver SD; Soliman AS
Breast Cancer Res Treat; 2008 Nov; 112(1):141-7. PubMed ID: 18058225
[TBL] [Abstract][Full Text] [Related]
28. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells.
Wu M; Wu ZF; Kumar-Sinha C; Chinnaiyan A; Merajver SD
Breast Cancer Res Treat; 2004 Mar; 84(1):3-12. PubMed ID: 14999149
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
[TBL] [Abstract][Full Text] [Related]
30. A p27(kip1)-binding protein, p27RF-Rho, promotes cancer metastasis via activation of RhoA and RhoC.
Hoshino D; Koshikawa N; Seiki M
J Biol Chem; 2011 Jan; 286(4):3139-48. PubMed ID: 21087931
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.
Bourguignon LY; Wong G; Earle C; Krueger K; Spevak CC
J Biol Chem; 2010 Nov; 285(47):36721-35. PubMed ID: 20843787
[TBL] [Abstract][Full Text] [Related]
32. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
33. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.
Singh B; Kinne HE; Milligan RD; Washburn LJ; Olsen M; Lucci A
PLoS One; 2016; 11(7):e0159072. PubMed ID: 27390851
[TBL] [Abstract][Full Text] [Related]
34. [Correlation of expression of RhoC with invasiveness of breast cancer cells in vitro].
Yuan Z; Su J; You JF; Wang JL; Cui XL; Zheng J
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):898-903. PubMed ID: 18478927
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.
Lacerda L; Debeb BG; Smith D; Larson R; Solley T; Xu W; Krishnamurthy S; Gong Y; Levy LB; Buchholz T; Ueno NT; Klopp A; Woodward WA
Breast Cancer Res; 2015 Mar; 17(1):42. PubMed ID: 25887413
[TBL] [Abstract][Full Text] [Related]
36. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk.
Arpaia E; Blaser H; Quintela-Fandino M; Duncan G; Leong HS; Ablack A; Nambiar SC; Lind EF; Silvester J; Fleming CK; Rufini A; Tusche MW; Brüstle A; Ohashi PS; Lewis JD; Mak TW
Oncogene; 2012 Feb; 31(7):884-96. PubMed ID: 21765460
[TBL] [Abstract][Full Text] [Related]
37. [Expressions and significances of PRL-3 and RhoC in A549 cell].
ZHANG P; ZHANG Z; LI X; LEI J; SU K; LI X; WANG X
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1160-4. PubMed ID: 21159255
[TBL] [Abstract][Full Text] [Related]
38. Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1.
Lin M; DiVito MM; Merajver SD; Boyanapalli M; van Golen KL
Mol Cancer; 2005 Jun; 4(1):21. PubMed ID: 15969750
[TBL] [Abstract][Full Text] [Related]
39. Molecular determinants of the inflammatory breast cancer phenotype.
Houchens NW; Merajver SD
Oncology (Williston Park); 2008 Dec; 22(14):1556-61; discussion 1561, 1565-8, 1576. PubMed ID: 19198217
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
